Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): D ata from randomized controlled trials

Monami, Matteo, Nreu, Besmir, Scatena, Alessia, Cresci, Barbara, Andreozzi, Francesco, Sesti, Giorgio, Mannucci, Edoardo·2017·Diabetes, Obesity and Metabolism
DOI 10.1111/dom.12926

Cited by (241)

Items 101–200 of 241

  1. Type 2 diabetes and cancer: problems and suggestions for best patient management
    Agostino Milluzzo, Paolo Giovanni Vigneri, Federica Martorana, Riccardo Vigneri, Laura Sciacca · 2020 · Exploration of Medicine
  2. Discovery and optimization of novel 3-benzyl-N-phenyl-1H-pyrazole-5-carboxamides as bifunctional antidiabetic agents stimulating both insulin secretion and glucose uptake
    Jeyun Jo, Dahae Lee, Yeong Hye Park, Hyeonjin Choi, Jin‐Hee Han, Do Hwi Park, You-Kyung Choi, Jinsook Kwak, Min-Kyu Yang, Jin‐Wook Yoo et al. · 2021 · European Journal of Medicinal Chemistry
  3. Obesity and Pancreatic Diseases: From Inflammation to Oncogenesis and the Impact of Weight Loss Interventions
    Mariana Souto, Tiago Cúrdia Gonçalves, José B. Cotter · 2025 · Nutrients
  4. Crosstalk between incretin hormones, Th17 and Treg cells in inflammatory diseases
    Eloísa Martins da Silva, Victor Yuji Yariwake, Renan Willian Alves, Daniele Ribeiro de Araújo, Vinícius Andrade‐Oliveira · 2022 · Peptides
  5. Glucagon-Like Peptide 1–Based Therapies and Risk of Pancreatic Cancer in Patients With Diabetes and Obesity
    Arunkumar Krishnan, Yousaf Bashir Hadi, William R. Hutson, Shyam J Thakkar, Shailendra Pratap Singh · 2022 · Pancreas
  6. Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017–2022
    Christopher E. Gaw, Hannah L. Hays, Cydney A. Kemp, Sandhya Kistamgari, Henry A. Spiller, Natalie I. Rine, Allison L. Rhodes, Motao Zhu, Gary A. Smith · 2024 · Journal of Medical Toxicology
  7. A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes – 2nd edition (English version)
    Ryotaro Bouchi, Tatsuya Kondo, Yasuharu Ohta, Atsushi Goto, Daisuke Tanaka, Hiroaki Satoh, Daisuke Yabe, Rimei Nishimura, Norio Harada, Hideki Kamiya et al. · 2024 · Journal of Diabetes Investigation
  8. A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes—2nd Edition (English version)
    Ryotaro Bouchi, Tatsuya Kondo, Yasuharu Ohta, Atsushi Goto, Daisuke Tanaka, Hiroaki Satoh, Daisuke Yabe, Rimei Nishimura, Norio Harada, Hideki Kamiya et al. · 2024 · Diabetology International
  9. Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance
    De Fano, Michelantonio, Malara, Massimo, Vermigli, Cristiana, Murdolo, Giuseppe · 2024 · International Journal of Molecular Sciences
  10. Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population
    D. Funch, Kathleen M. Mortimer, N. Ziyadeh, J. Seeger, Ling Li, Heather Norman, A. Major-Pedersen, H. Bosch-Traberg, H. Gydesen, D. Dore · 2019 · Diabetes, obesity and metabolism
  11. Association between glucagon‐like peptide‐1 receptor agonists and biliary‐related diseases in patients with type 2 diabetes: A nationwide cohort study
    Dong, Yaa‐Hui, Wu, Jo‐Hsuan, Chang, Chia‐Hsuin, Lin, Jou‐Wei, Wu, Li‐Chiu, Toh, Sengwee · 2022 · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
  12. No pancreatic safety concern following glucagon‐like peptide‐1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials
    Ye Liu, Qing Tian, Jin Yang, Haining Wang, Tianpei Hong · 2018 · Diabetes/Metabolism Research and Reviews
  13. Personalized Management of Type 2 Diabetes
    Patricia R. Peter, Beatrice C. Lupsa · 2019 · Current Diabetes Reports
  14. GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways
    Daniela Lucente, Stefania Bellino, Anna La Salvia · 2025 · Genes
  15. GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians
    Bibek Saha, Vijayvardhan Kamalumpundi, Don Chamil Codipilly · 2025 · Mayo Clinic Proceedings
  16. Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities
    Riccardo Sarzani, Matteo Landolfo, Chiara Di Pentima, Beatrice Ortensi, Paolo Falcioni, Lucia Sabbatini, Adriano Massacesi, Ilaria Rampino, Francesco Spannella, Federico Giulietti · 2024 · Frontiers in Medicine
  17. Use of glucagon‐like peptide‐1 receptor agonists for pediatric patients with obesity and diabetes: The providers' perspectives
    Evgenia Gourgari, Lina Huerta‐Saenz, Ksenia N. Tonyushkina, Elizabeth T. Rosolowsky, Ines Guttmann‐Bauman · 2021 · Pediatric Diabetes
  18. Risk of all–cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network
    Enrico Tartaglia, Tommaso Bucci, Michele Rossi, Andrea Galeazzo Rigutini, Amir Askarinejad, Uazman Alam, Katarzyna Nabrdalik, Giuseppe Boriani, Gregory Y.H. Lip · 2025 · Cardiovascular Diabetology
  19. Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility
    Henriette Holst Nerild, Andreas Brønden, Ida M. Gether, Pernille H. Hellmann, Mille Baekdal, Matthew Paul Gillum, Jens Skjoldan Svenningsen, Bolette Hartmann, Naveen Rathor, Hanna Angelene et al. · 2023 · Diabetes Obesity and Metabolism
  20. Diagnosis and Non-Invasive Treatment of Obesity in Adults with Type 2 Diabetes Mellitus: A Review of Guidelines
    Michał Łuniewski, Beata Matyjaszek‐Matuszek, Monika Lenart-Lipińska · 2023 · Journal of Clinical Medicine
  21. Exploring the potential impact of GLP-1 receptor agonists in cancer therapy
    Baseer Aslam, Muhammad Daim Bin Zafar, Mah I Kan Changez, Muhammad ABDULLAH, Muhammad Safwan, Bisma QAMAR, Abdullah SHINWARI, Sanjana RAI · 2023 · Minerva Endocrinology
  22. Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice
    Megan O. Bensignor, Silva A Arslanian, Mary Ellen Vajravelu · 2024 · Current Opinion in Pediatrics
  23. Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals
    Jorge Felipe Argenta Model, Débora Santos Rocha, Alessa da C Fagundes, Anapaula Sommer Vinagre · 2022 · Veterinary and Animal Science
  24. Drug-drug interactions when treating HIV-related metabolic disorders
    María del Mar Gutiérrez, Gracia María Mateo, Noemí Corbacho, Francesc Vidal, Peré Domingo · 2019 · Expert Opinion on Drug Metabolism & Toxicology
  25. Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown
    Edoardo Mannucci, Ilaria Dicembrini · 2026 · Nature Reviews Clinical Oncology
  26. GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy
    Ahlima Roumane, George D. Mcilroy, Nadine Sommer, Weiping Han, Lora K. Heisler, Justin J. Rochford · 2024 · Frontiers in Endocrinology
  27. The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study
    Mohammed Ali Gameil, Elshahat Ali Ahmed Mohamed Yousef, Rehab Elsayed Marzouk, Mohamed Emara, Abeer Hussein Abdelkader, Rasha Ibrahim Salama · 2024 · Diabetology & Metabolic Syndrome
  28. Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis
    Long He, Jinwei Li, Xiong Cheng, Li Luo, Yilan Huang · 2025 · Frontiers in Pharmacology
  29. Therapy of Type 2 Diabetes
    Landgraf, Rüdiger, Aberle, Jens, Birkenfeld, Andreas L., Gallwitz, Baptist, Kellerer, Monika, Klein, Harald, Müller-Wieland, Dirk, Nauck, Michael A., Wiesner, Tobias, Siegel, Erhard · 2022 · Experimental and Clinical Endocrinology & Diabetes
  30. Meta-analysis of the association between new hypoglycemic agents and digestive diseases
    Yuwen Wang, Jin-Hao Lin, Cui-Shan Yang · 2022 · Medicine
  31. Diagnosis and treatment of post-cholecystectomy diarrhoea
    Rang-Lang Huang, Wen-Kai Huang, Xiang-Yi Xiao, Linyuan Ma, He-Zi-Rui Gu, Guoping Yang · 2023 · World Journal of Gastrointestinal Surgery
  32. Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!
    Dimitrios Patoulias, Massimiliano Caprio, Anca Pantea Stoian, Manfredi Rizzo · 2023 · Expert Opinion on Drug Safety
  33. Weight reduction and the risk of gallbladder and biliary disease: A systematic review and meta‐analysis of randomized clinical trials
    Yang, Wenjia, Wu, Han, Cai, Xiaoling, Lin, Chu, Luo, Yingying, Hu, Suiyuan, Li, Zonglin, Jiao, Ruoyang, Bai, Shuzhen, Liu, Geling et al. · 2024 · Obesity Reviews
  34. Management of Diabetes Mellitus in Acromegaly and Cushing’s Disease with Focus on Pasireotide Therapy: A Narrative Review
    Michelantonio De Fano, Alberto Falorni, Massimo Malara, Francesca Porcellati, Carmine Giuseppe Fanelli · 2024 · Diabetes Metabolic Syndrome and Obesity
  35. Semaglutide injection for the treatment of adults with type 2 diabetes
    Richard A. Chudleigh, Stephen Charles Bain · 2020 · Expert Review of Clinical Pharmacology
  36. A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes
    Margarita Barrientos Pérez, Daniel S. Hsia, Lance Alan Sloan, Haylene Nell, Ounisha Mungur, Lionel Hovsepian, Wolfgang Schmider, Robert Spranger, Na Yang, Elisabeth Niemoeller · 2022 · Pediatric Diabetes
  37. Diabetes Care for Patients Experiencing Homelessness: Beyond Metformin and Sulfonylureas
    Lauren K. Brooks, Nilesh Kalyanaraman, Rana Malek · 2018 · The American Journal of Medicine
  38. Dose-dependent pancreatitis risk associated with GLP-1 agonists
    Joyce Hanyue Gu, Mark Samarneh · 2025 · Journal of Diabetes & Metabolic Disorders
  39. α-Methyl- l -tryptophan as a weight-loss agent in multiple models of obesity in mice
    Sathish Sivaprakasam, Sabarish Ramachandran, Mohd Omar Faruk Sikder, Yangzom Doma Bhutia, Mitchell W. Wachtel, Vadivel Ganapathy · 2021 · Biochemical Journal
  40. Does Incretin Agonism Have Sustainable Efficacy?
    Sok‐Ja Janket, Miyo K. Chatanaka, Dorsa Sohaei, Faleh Tamimi, Jukka H. Meurman, Eleftherios P. Diamandis · 2024 · Cells
  41. GLP-1 Receptor Agonists Initiation and Risk of Acute Pancreatitis and Pancreatic Cancer: A Real-World Comparative Study
    Omar Faour, Moheb Boktor, Hanford Yau, Mustafa Kinaan, Ishak A. Mansi · 2025 · American Journal of Medicine Open
  42. GLP-1 Receptor Agonists and Noncardiometabolic Outcomes
    Kaijie Yang, Changyuan Liu, Qiqiang Guo, Yongze Li · 2026 · JAMA Network Open
  43. An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes
    Ping Wu, Zhenyu Liu, Xiaohong Jiang, Hao Fang · 2019 · Current Drug Targets
  44. The Preventive Effects of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Cancer Metastasis: A Network Meta-Analysis of 67 Randomized Controlled Trials
    Chih‐Wei Hsu, Bing‐Syuan Zeng, Chih‐Sung Liang, Bing‐Yan Zeng, Chao‐Ming Hung, Brendon Stubbs, Yen‐Wen Chen, Wei‐Te Lei, Jiann-Jy Chen, Po‐Huang Chen et al. · 2025 · International Journal of Molecular Sciences
  45. GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective
    Roy R. Rasalam, John Barlow, Mark Kennedy, Pat Phillips, Alan F. Wright · 2019 · Diabetes Therapy
  46. Association of glucagon-like peptide-1 receptor agonists and seven common mental disorders: A drug target and mediation Mendelian randomization
    Zexin Zhang, Shu Li, Xinyue Dai, Cong Li, Sun Pengfei, Jianwen Qu, Haiyue Jiang, Bo Pan · 2025 · Journal of Affective Disorders
  47. [Retracted] The Association between the Risk of Esophageal Cancer and Type 2 Diabetes Mellitus: An Updated Meta‐Analysis
    Runquan Zhou, Chenglu Huang, Zhilin Luo, Tianhu Wang · 2022 · BioMed Research International · Retracted
  48. The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study
    Zhiyuan Cheng, Shuang Wang, Fu‐Rong Li, Cheng Jin, Chunbao Mo, Jing Zheng, Xia Li, Fengchao Liang, Jin-Kui Yang, Dongfeng Gu · 2024 · Journal of Diabetes
  49. Glucagon‐like Peptides (GLP‐1) Perspectives in Synucleinopathies Treatment
    Thomas Foltynie, Dilan S. Athauda · 2018 · Movement Disorders Clinical Practice
  50. Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
    Marion L. Vetter, Kristina M. Johnsson, Elise Hardy, Hui Wang, Nayyar Iqbal · 2019 · Diabetes Therapy
  51. Changing the approach to type 2 diabetes treatment: A comparison of glucagon‐like peptide‐1 receptor agonists and sulphonylureas across the continuum of care
    Marco Orsini Federici, Raffaella Gentilella, Antonella Corcos, Enrico Torre, Stefano Genovese · 2021 · Diabetes/Metabolism Research and Reviews
  52. Establishment of a Prognostic Model for Hepatocellular Carcinoma Based on Bioinformatics and the Role of NR6A1 in the Progression of HCC
    Zhong-Hua Lin, Jie Zhang, Li-Kun Zhuang, Yongning Xin, Shiying Xuan · 2022 · Journal of Clinical and Translational Hepatology
  53. Glucagon-like peptide-1 receptor agonists: Evolution, gastrointestinal adverse effects, and future directions
    Alaa Ismail, Mohab Sherif Amer, Ahmed Tawheed · 2025 · World Journal of Gastrointestinal Pharmacology and Therapeutics
  54. Comparative Safety of GLP-1 Receptor Agonists Across Gastrointestinal, Renal and Pancreatic Systems
    Hala Shokr, Mohamed A. Mekkawy, Ali Mawfek Khaled Hindi · 2026 · Pharmaceuticals
  55. Medical Management of Obesity: Current Trends and Future Perspectives
    Andrés Calderón, Maria Aguilera-Astudillo, Alexsandra P. Rojas, Samaneh Dowlatshahi, Abhishek Kansara, Jawairia Shakil, Bhargavi Patham · 2025 · Methodist DeBakey Cardiovascular Journal
  56. The new type 2 diabetes mellitus therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium–glucose cotransporter 2) inhibitors
    Claudio Borghi, Alessio Bragagni · 2020 · European Heart Journal Supplements
  57. Therapy of Type 2 Diabetes
    Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller‐Wieland, Michael Albrecht Nauck, Tobias Wiesner, Erhard G. Siegel · 2024 · Experimental and Clinical Endocrinology & Diabetes
  58. Review Article: The Evolving Role of GLP ‐1 Receptor Agonists in Gastroenterology Practice
    Sydney F. Pomenti, Annabel R. Gerber, David A. Katzka, Michael Camilleri, Chin Hur · 2025 · Alimentary Pharmacology & Therapeutics
  59. Acute Kidney and Liver Injury Associated With Low-Dose Liraglutide in an Obese Adolescent Patient
    Rinat Komargodski, Avigail Wittenberg, Hilla Bahat, Marianna Rachmiel · 2024 · PEDIATRICS
  60. Foeniculum vulgare (Fennel): A comprehensive review of its anti-diabetic properties
    Nozizwe Hillary Ncube, Jeena Gupta · 2025 · Asian Pacific Journal of Tropical Biomedicine
  61. Basic Concepts in Insulin Resistance and Diabetes Treatment
    Fernando Bril, Kenneth J. Cusi · 2017 · Springer eBooks
  62. Recent Advances in Anti-Obesity Drugs
    Jang Won Son · 2022 · Journal of Korean Diabetes
  63. Therapie des Typ-2-Diabetes
    Rüdiger Landgraf, Monika Kellerer, Jens Aberle, Eva-Maria Fach, Baptist Gallwitz, Andreas Hamann, Hans‐Georg Joost, Harald Klein, Dirk Müller‐Wieland, Michael Albrecht Nauck et al. · 2019 · Der Diabetologe
  64. Glucagon‐Like Peptide‐1 Analogues and the Risk of Recurrent Pancreatitis in Diabetic Patients With History of Pancreatitis or Elevated Lipase: Retrospective Cohort Analysis
    Bronya Calvarysky, Yaara Gal, Shiri Kushnir, ‪Adi Turjeman‬‏, Tzippy Shochat, Idit Dotan, Talia Diker‐Cohen · 2025 · Diabetes/Metabolism Research and Reviews
  65. Obesity, type 2 diabetes and cancers of the digestive system
    Simona Cernea, Dana Crișan, Cristina-Mihaela Lăcătușu, Oana‐Patricia Zaharia, Sofiya Gancheva · 2026 · Seminars in Cancer Biology
  66. A Case of Intussusception With Bowel Obstruction in a Gastric Roux-en-Y Patient Prescribed Semaglutide
    Suresh K. Pavuluri, Ahmad Toumar, Andrew J. Duffy · 2025 · Journal of the American College of Emergency Physicians Open
  67. Methodologies for bioactivity assay: animal study
    Feiran Xu, Elvira González de Mejı́a · 2021 · Elsevier eBooks
  68. Therapie des Typ-2-Diabetes
    Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller‐Wieland, Michael Albrecht Nauck, Tobias Wiesner, Erhard G. Siegel · 2022 · Die Diabetologie
  69. Magnetic resonance imaging for acute pancreatitis in type 2 diabetes patients
    Yan-Hui Ni, Ling-Ji Song, Bo Xiao · 2023 · World Journal of Clinical Cases
  70. Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?
    Conor F. Murphy, Carel Wynand le Roux · 2018 · Annals of Translational Medicine
  71. Liraglutide use in pediatric type 2 familial partial lipodystrophy caused by LMNA mutation: a case report
    Youran Li, Ronghua Yu, Ting Song, Yongmei Xiao, Wuhen Xu, Ting Zhang, Xiaolu Li · 2025 · BMC Pediatrics
  72. Comparative risk of infections with GLP-1 receptor agonists versus SGLT2 inhibitors in patients with advanced chronic kidney disease and type 2 diabetes
    Ching-Chung Hsiao, Jia-Jin Chen, Shu-Chun Huang, Chieh‐Li Yen, Wen-Yu Ho, Yu-Wei Fang, Mon‐Ting Chen, Jeng How Yang, Ming‐Hsien Tsai · 2026 · Diabetes Research and Clinical Practice
  73. Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors
    Yan Zhou, Jiankun Zhu, Haiya Wu, Yuying Deng, Qiuhe Ji · 2021 · Diabetes Therapy
  74. Current pharmacological approaches in obesity treatment
    Pelin TİRYAKİOĞLU, Huseyin Yilmaz, İsmail Demir, İsmail Yılmaz · 2023 · DAHUDER Medical Journal
  75. Severe, Complicated Pancreatitis With an Unclear Etiology
    Brian Nohomovich, Ali Akbar Shah, Neil Hughes · 2023 · Cureus
  76. Targeting postprandial glycaemia in children with diabetes: O pportunities and challenges
    Myfanwy C. Geyer, Christopher Keith Rayner, Michael Horowitz, Jennifer Couper · 2017 · Diabetes Obesity and Metabolism
  77. The contemporary landscape of cardiovascular optimization in type 2 diabetes: overcoming barriers to evidence-based use of newer antihyperglycemic agents
    Konstantinos Malas, Salman Kazmi, Yu Mi Kang, Darren K. McGuire · 2025 · Expert Opinion on Pharmacotherapy
  78. Comparative Risk of Adverse Pancreatic Events With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas Among Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk
    Urja N Kalathiya, Jeph S. Herrin, KAVYA SINDHU SWARNA, Yihong Deng, Eric C. Polley, Joshua J. Neumiller, Rodolfo Javier Galindo, Guillermo E. Umpierrez, Joseph S. Ross, Mindy M. Mickelson et al. · 2025 · Endocrine Practice
  79. Successful Use of Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Recurrent Hypertriglyceridemia-Induced Pancreatitis
    Chinmay Guralwar, Shuji Mitsuhashi, Motaz H. Ashkar, Victor G Chedid · 2025 · ACG Case Reports Journal
  80. Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon‐Like Peptide‐1 Receptor Agonists in Type 2 Diabetes
    Mohamed H. Eldesouki, Omar Alkasabrah, Mohammed Kloub, Hazem Maarouf Abosheaishaa, Khaled Elfert, Arpit Sharma, Sherif Andrawes, Nikki K. Duong · 2026 · United European Gastroenterology Journal
  81. Pancreatic Safety in Studies of The Glucagon-Like Peptide-1 Receptor Agonist Albiglutide
    Firas Al‐Kawas, Michelle Ann Anderson, Robert Enns, Timoth y. H. Wilson, SUSAN L. JOHNSON, Jason M. Mallory · 2019 · Endocrine Practice
  82. Bridging the Gap Between Diabetes and Cardiovascular Disease: A Comparative Review of Different Glucagon-Like Peptide-1 (GLP-1) Agonists: Efficacy, Safety, and Patient Outcomes
    Feras A Alghamdi, Hussein Alshegifi, Reema Alhuthayli, Turki Helal, Turki A Huwait, Turki Alharbi, Abdulrahman F Akbar, Wejdan Alshehri, Sultan Alsheikh · 2024 · Cureus
  83. DNA methylation biomarker analysis from low-survival-rate cancers based on genetic functional approaches
    Yi-Hsuan Tsai, Prasenjit Mitra, David Taniar, Tun‐Wen Pai · 2025 · Frontiers in Bioinformatics
  84. Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
    Anna Pietraszek · 2020 · Current Drug Safety
  85. Fatty Pancreas: An Underappreciated Intersection of the Metabolic Profile and Pancreatic Adenocarcinoma
    Arthur Swislocki · 2021 · Metabolic Syndrome and Related Disorders
  86. Avoiding and managing the side effects of type 2 diabetes treatments
    David Morris · 2023 · Journal of Prescribing Practice
  87. Role of combination therapy or coformulation products in treatment of type 2 diabetes
    Jennifer M. Trujillo · 2018 · Pharmacy Today
  88. ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide
    Antonio Carlo Bossi, Valentina De Mori, Cristiana Scaranna, Giovanni Veronesi, Giuseppe Lepore, the ANDREW study group, Agosti Barbara, Bellante Rosalia, Belviso Antonio, Denise Berzi et al. · 2020 · Diabetes Therapy
  89. The gallbladder in diabetes
    Rowan Hillson · 2021 · Practical Diabetes
  90. Therapie des Typ-2-Diabetes
    Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller‐Wieland, Michael Albrecht Nauck, Tobias Wiesner, Erhard G. Siegel · 2023 · Die Diabetologie
  91. Asymptomatic Subcutaneous Semaglutide Overdose: A Case Report and Literature Review
    Courtney B. Diec, Elizabeth A. Cook, Nguyet T. Nguyen · 2025 · Journal of Pharmacy Practice
  92. Glucagon‐Like Peptide‐1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction
    Ramzi Ibrahim, William Han, Winston T. Wang, Ethan Kau, Nada Said, Beani J. Forst, Hoang Nhat Pham, Mahmoud Hassan Abdelnabi, Mohammed Salih, Nima Baba Ali et al. · 2025 · Journal of the American Heart Association
  93. Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
    Alexandria TM Lee, C H Park, Zhaohui Arter, Misako Nagasaka, Sai-Hong Ou · 2025 · Lung Cancer Targets and Therapy
  94. Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
    Jang Won Son · 2026 · Journal of Korean Medical Association
  95. A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
    Andrew-Hyun Lee, Deborah Jane Holmes-Walker · 2026 · Healthcare
  96. Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy
    Shreyas Krishna, Kathleen Marie Dungan, Raj Shah, Zobeida Cruz‐Monserrate, Kathleen E. DelGiorno, Marcus Tan, Phil A. Hart · 2026 · npj gut and liver.
  97. Incretin-Based Therapies: Revisiting Their Mode of Action
    Brian Thomas Layden, Barton L. Wicksteed, Franck Mauvais‐Jarvis · 2017 · Endocrinology
  98. Insulin Resistance Is a Common Core Tethered to Diabetes and Pancreatic Cancer Risk
    Henu Kumar Verma, Lakkakula VKS Bhaskar · 2019 · Springer eBooks
  99. Diabesity and the Kidney
    Mohamed Essam Elrggal, Ahmed Fathy Elkeraie, Sol M. Carriazo, Hany Sawaf, Si Yuan Khor, Yasmine Elkeraie, Issa R. Haddad, Khaled Moustafa, Mohamed M. Hassanein · 2023 · Frontiers in clinical drug research. Diabetes and obesity
  100. Therapie des Typ-2-Diabetes
    Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller‐Wieland, Michael Albrecht Nauck, Tobias Wiesner, Erhard G. Siegel · 2024 · Die Diabetologie